Monte Rosa Therapeutics, Inc.
NASDAQ:GLUEBiotechnology
Healthcare
$8.91 -1.39%
-$0.26 today
- Market cap
- $761.36M
- Beta
- 1.60
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.98
52W Low $4.12High $25.77
Volume 1.11M
Average 1.02M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$22.80M
FY 2025 · Annual
Investing Cash Flow
-$101.83M
FY 2025 · Annual
Financing Cash Flow
$30.35M
FY 2025 · Annual
-69.3% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (73.96M) | (108.5M) | (135.35M) | (72.7M) | (38.63M) |
| Depreciation & Amortization | 2.13M | 3.75M | 6.22M | 8.12M | 8.36M |
| Deferred Income Tax | 17K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.2M | 11.66M | 16.67M | 18.13M | 18.87M |
| Change in Working Capital | 6.29M | (2.13M) | 72.47M | 91.4M | (9.19M) |
| Accounts Receivables | 0 | (187) | 1.9M | 332K | (7M) |
| Inventory | 0 | 187 | 0 | 0 | 0 |
| Accounts Payables | (706K) | (744K) | 5.76M | 6.25M | (13.71M) |
| Other Working Capital | 6.99M | (1.39M) | 64.81M | 84.81M | 11.52M |
| Other Non-Cash Items | 960K | 2.76M | (3.81M) | (2.95M) | (2.2M) |
| Operating Cash Flow | (59.36M) | (92.47M) | (43.8M) | 42M | (22.8M) |
| Capital Expenditures | (9.73M) | (12.91M) | (19.04M) | (3.99M) | (4.7M) |
| Acquisitions (Net) | 79K | 109K | 62K | 0 | 0 |
| Purchases of Investments | 0 | (384.42M) | (103.15M) | (230.36M) | (376.68M) |
| Sales of Investments | 0 | 178M | 210.93M | 189.9M | 279.54M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (9.65M) | (219.22M) | 88.8M | (44.45M) | (101.83M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 237.75M | 20.06M | 27.49M | 944K | 30.35M |
| Common Stock Repurchased | 0 | 0 | 0 | (641K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.19M) | 411K | 0 | 98.59M | 0 |
| Financing Cash Flow | 377.56M | 20.47M | 27.49M | 98.89M | 30.35M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 308.55M | (291.22M) | 72.49M | 96.44M | (94.28M) |
| Free Cash Flow | (69.1M) | (105.38M) | (62.84M) | 38.01M | (27.5M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$38.6M
+ D&A$8.4M
+ Stock-Based Comp$18.9M
+ Deferred Tax$0
- Working Capital-$9.2M
- Other Non-Cash-$2.2M
= Operating Cash Flow-$22.8M
- Capex-$4.7M
= Free Cash Flow-$27.5M
Analysis
FY2025 free cash flow is -$27.5M. FCF conversion is 71.2% of net income. Operating cash flow was -$22.8M, with capex of -$4.7M. The largest bridge item is Stock-Based Comp at $18.9M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 6, 2026 | |
| 8-K | Current report | Oct 1, 2026 | |
| 8-K | Current report | Sep 8, 2026 |
Does GLUE generate free cash flow?
Monte Rosa Therapeutics, Inc. (GLUE) generated -$27.50M of free cash flow in fiscal 2025.
How much operating cash flow does GLUE produce?
Operating cash flow was -$22.80M, before capital expenditures of $4.70M.
Continue the stock analysis
Jump to another research area for this company.